康华生物
(300841)
| 流通市值：70.52亿 | | | 总市值：77.68亿 |
| 流通股本：1.22亿 | | | 总股本：1.35亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 762,341,572.72 | 770,074,519.38 | 1,007,828,965.84 | 1,039,366,021.16 |
| 应收票据及应收账款 | 1,393,896,195.41 | 1,430,148,717.53 | 1,361,642,355.65 | 1,410,519,392.7 |
| 其中：应收票据 | 700,000 | - | - | - |
| 应收账款 | 1,393,196,195.41 | 1,430,148,717.53 | 1,361,642,355.65 | 1,410,519,392.7 |
| 预付款项 | 10,568,889.01 | 13,322,348.47 | 18,910,765.44 | 17,093,688.38 |
| 其他应收款合计 | 13,285,137.56 | 13,258,862.62 | 16,952,135.85 | 16,382,086.18 |
| 存货 | 180,436,269.87 | 193,763,461.09 | 189,113,400.9 | 173,536,297.45 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,360,528,064.57 | 2,420,567,909.09 | 2,644,447,623.68 | 2,656,897,485.87 |
| 非流动资产: | | | | |
| 长期股权投资 | 6,500,000 | 6,500,000 | 6,500,000 | 6,500,000 |
| 其他非流动金融资产 | 461,745,354.2 | 466,293,841.37 | 471,392,714.03 | 470,871,012.97 |
| 固定资产 | 840,217,214.48 | 825,965,040.68 | 838,409,092.53 | 849,035,159.71 |
| 在建工程 | 124,408,297.53 | 119,379,650.21 | 111,155,216.74 | 112,254,436.74 |
| 无形资产 | 15,829,180.83 | 15,776,156.94 | 15,372,942.88 | 15,375,932.99 |
| 长期待摊费用 | 137,019,441.7 | 117,415,454.47 | 107,008,337.39 | 94,389,764.96 |
| 递延所得税资产 | 525,073.85 | 1,247,742.53 | - | - |
| 其他非流动资产 | 3,994,313.5 | 6,561,941.9 | 7,448,050.86 | 3,944,519 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,590,238,876.09 | 1,559,139,828.1 | 1,557,286,354.43 | 1,552,370,826.37 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,950,766,940.66 | 3,979,707,737.19 | 4,201,733,978.11 | 4,209,268,312.24 |
| 流动负债: | | | | |
| 短期借款 | 216,432,123.41 | 176,401,929 | 210,191,877.41 | 190,913,849.93 |
| 应付票据及应付账款 | 6,151,719.05 | 6,218,911.5 | 11,269,734.88 | 7,129,147.17 |
| 其中：应付票据 | 937,615.11 | - | - | 4,000,000 |
| 应付账款 | 5,214,103.94 | 6,218,911.5 | 11,269,734.88 | 3,129,147.17 |
| 合同负债 | 105,605.83 | 207,372.82 | 184,511.39 | 295,511.18 |
| 应付职工薪酬 | 20,616,419.74 | 17,396,965.67 | 14,370,460.44 | 34,942,933.81 |
| 应交税费 | 11,775,775.78 | 22,474,380.21 | 17,144,179.06 | 42,217,146.97 |
| 其他应付款合计 | 230,947,075.66 | 306,556,812.89 | 335,362,150.06 | 406,217,416.78 |
| 其他流动负债 | 3,168.17 | 6,221.18 | 5,535.34 | 8,865.34 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 486,031,887.64 | 529,262,593.27 | 588,528,448.58 | 681,724,871.18 |
| 非流动负债: | | | | |
| 预计负债 | 3,809,053.37 | 3,222,290.15 | 4,024,237.25 | 4,792,273.24 |
| 递延收益 | 6,167,000 | 6,182,456.4 | 6,197,177.1 | 6,199,754.1 |
| 递延所得税负债 | - | - | 1,897,991.22 | 2,499,666.34 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 9,976,053.37 | 9,404,746.55 | 12,119,405.57 | 13,491,693.68 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 496,007,941.01 | 538,667,339.82 | 600,647,854.15 | 695,216,564.86 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 134,650,449 | 134,650,449 | 134,650,449 | 134,650,449 |
| 资本公积 | 1,179,543,389.54 | 1,179,543,389.54 | 1,179,543,389.54 | 1,179,543,389.54 |
| 减:库存股 | 323,095,166.03 | 237,466,383.75 | 185,530,157.25 | 123,097,539.84 |
| 盈余公积 | 67,325,224.5 | 67,325,224.5 | 67,325,224.5 | 67,325,224.5 |
| 未分配利润 | 2,396,335,102.64 | 2,296,987,718.08 | 2,405,097,218.17 | 2,255,630,224.18 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,454,758,999.65 | 3,441,040,397.37 | 3,601,086,123.96 | 3,514,051,747.38 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,454,758,999.65 | 3,441,040,397.37 | 3,601,086,123.96 | 3,514,051,747.38 |
| 负债和股东权益合计 | 3,950,766,940.66 | 3,979,707,737.19 | 4,201,733,978.11 | 4,209,268,312.24 |
| 公告日期 | 2024-10-29 | 2024-08-17 | 2024-04-24 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |